-
The Prostate Cancer Drug Market Opens in a new window)
A new analysis of the pipeline of novel therapies for prostate cancer, such as PARP inhibitors, PSMA-targeted radioligands and AKT inhibitors - and their potential market impact. -
Novavax’s Effort to Vaccinate the World, From Zero to Not Quite Warp Speed Opens in a new window)
Novavax’s quest to scale up operations underscores how difficult it can be to launch a vaccine ― even with the formula and technology in hand. So what happened?Comments
-
FDA New Drug Approvals in Q2 2021 Opens in a new window)
Among the 13 FDA approvals during the second quarter of 2021, one has undoubtedly been the biggest talking point - Biogen’s Alzheimer disease drug Aduhelm (aducanumab).Comments
-
The Adoption of Drug Technology
Nearly 90 percent of newly launched medicines are available in the United States.Comments
-
Annual Report to the Nation on the Status of Cancer Opens in a new window)
Jointly issued by the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the North American Association of Central Cancer Registries (NAACCR), and the National Cancer Institute (NCI).Comments
-
Transparency in Prescription Drug Pricing: Recent State and Federal Developments to Watch Opens in a new window)
In the last five years, 18 states have passed legislation requiring prescription drug manufacturers to disclose certain price information for their drugs.Comments
-
Innovation on Hold During the Pandemic? FDA Says No With 29 Approvals in First Half of 2021 Opens in a new window)
With the U.S. FDA endorsing its 29th novel drug on June 30, the drug industry was slightly ahead of last year’s pace.Comments
-
Biopharma Takeovers Dry Up Opens in a new window)
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?Comments
-
Live Updates: July 2021 Drug Price Increases Opens in a new window)
Another July, another round of drug price hikes in America.Comments
-
Patient Drug Prices Can Vary by $50 a Pill Among U.S. Hospitals Opens in a new window)
The Trump administration’s effort to require hospitals to disclose their rates in a “consumer-friendly format” was praised by patients and employers who worried the lack of transparency kept prices high.Comments
-
‘Extreme’ Price Increases of Antiparasitics Tied to Higher Treatment Costs Opens in a new window)
“Extreme” drug price increases for antiparasitic medication were associated with increased total outpatient treatment costs, or TOCs.Comments
-
Costs and Savings under Federal Policy Approaches to Address Medicaid Prescription Drug Spending Opens in a new window)
This brief analyzes leading federal approaches to address Medicaid prescription drug spending, discusses (where available) a range of cost estimates for each policy, and assesses what drives those estimates or where there is uncertainty in them.Comments
Comments